GlycoMimetics

Health biotech drug development oncology pharma

GlycoMimetics is a clinical-stage biotechnology company. The Company uses novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. Its products include GMI-1070, a synthetic glycomimetic molecule designed to inhibit selectin types, such as E, P, and L-selectin; and GMI-1051, a small molecular weight compound for the treatment or prevention of infections caused by pseudomonas aeruginosa.

Market capitalization(2018-06-14)

$698.2 M

Type

Public

Rockville, US

Founded

2003

Size (employees)

42 (est)

Website

glycomimetics.com

GlycoMimetics was founded in 2003 and is headquartered in Rockville, US

Report incorrect company information

Key People/Management at GlycoMimetics

Brian Hahn

CFO

John Baldwin

Director

Michael Henos

Director

Franklin H. Top

Director

William Gust

Director

M. James Barrett

Chairman of the Board of Directors

Report incorrect company information

GlycoMimetics Office Locations

GlycoMimetics has an office in Rockville

Rockville, US (HQ)

9708 Medical Center Dr

Show all (1)

Report incorrect company information

GlycoMimetics Financials and Metrics

GlycoMimetics Financials

GlycoMimetics's revenue was reported to be $18.50 k in FY, 2016 which is a 99.9% decrease from the previous period.

Summary

USD
EBIT (Q1, 2018)	(11.9 m)
Market capitalization (14-Jun-2018)	698.2 m
Closing share price (14-Jun-2018)	16.4
Cash (31-Mar-2018)	242.6 m

GlycoMimetics's current market capitalization is $698.2 m.

Income Statement

Annual

USD	FY, 2014	FY, 2015	FY, 2016
Revenue	15 m	20.1 m	18.5 k
Revenue growth, %		34%	(100%)
EBIT	(11.1 m)	(12.8 m)
EBIT margin, %	(74%)	(64%)

Quarterly

USD	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q3, 2017
Net Income	2.9 m	(3.7 m)	(7.1 m)	3.3 m	(3.9 m)	(7.6 m)	(15.6 m)	(23.5 m)	(7.9 m)	(24 m)

show all

Balance Sheet

Annual

USD	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Cash	55.2 m	46.8 m	40 m	123.9 m
Accounts Receivable			13.6 m
Inventories	916.2 k	441.8 k	478.5 k
Current Assets	56.1 m	47.2 m	40.5 m	127.2 m

Quarterly

USD	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017	Q1, 2018
Cash	57 m	66.2 m	61.4 m	46.6 m	40.2 m	53.8 m	38.8 m	53.1 m	45.3 m	34.6 m	119.1 m	112.9 m	242.6 m
Accounts Receivable					20 m
Inventories												1 m
Current Assets	57.7 m	67.1 m	61.9 m	47.3 m	60.8 m	54.5 m	39.5 m	54.5 m	46.5 m	35.3 m	119.7 m	113.9 m	246.1 m

show all

Cash Flow

Annual

USD	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Net Income	(11.1 m)	(12.8 m)	(31.8 m)	(33.3 m)
Depreciation and Amortization	158.7 k	191.5 k	190.5 k	263.5 k
Inventories	1.7 m	474.4 k	(36.7 k)
Accounts Payable	(270.9 k)	(309.8 k)	1 m	1.1 m

Quarterly

USD	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017	Q1, 2018
Net Income	(5.1 m)	2.9 m	(3.7 m)	(7.1 m)	3.3 m	(3.9 m)	(7.6 m)	(15.6 m)	(23.5 m)	(7.9 m)	(16.1 m)	(24 m)	(11.5 m)
Depreciation and Amortization	34.6 k	73.5 k	114.3 k	44.2 k	90.5 k	142.4 k	47.2 k	93.9 k	139.7 k	54.3 k	123.9 k		68.8 k
Inventories												1 m
Accounts Payable	652.1 k	(672.7 k)	(561.2 k)	299.5 k	222.5 k	(240.9 k)	1 m	816.9 k	682.5 k	(1.1 m)	(990.1 k)	1.6 m	1.2 m